TY - JOUR
T1 - Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy
AU - Fujimura, Taku
AU - Yoshino, Koji
AU - Kato, Hiroshi
AU - Fujisawa, Yasuhiro
AU - Nakamura, Yoshiyuki
AU - Yamamoto, Yuki
AU - Kunimoto, Kayo
AU - Ito, Takamichi
AU - Matsushita, Shigeto
AU - Maekawa, Takeo
AU - Ohuchi, Kentaro
AU - Amagai, Ryo
AU - Muto, Yusuke
AU - Furudate, Sadanori
AU - Kambayashi, Yumi
AU - Hashimoto, Akira
AU - Aiba, Setsuya
N1 - Publisher Copyright:
© 2020 Japanese Dermatological Association
PY - 2021/3
Y1 - 2021/3
N2 - The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF-mutated advanced melanoma as second-line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF-mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second-line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first-line targeted therapy. In contrast, overall survival and progress-free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well-tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second-line therapy and beyond is comparable with that of first-line targeted therapy.
AB - The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF-mutated advanced melanoma as second-line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF-mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second-line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first-line targeted therapy. In contrast, overall survival and progress-free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well-tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second-line therapy and beyond is comparable with that of first-line targeted therapy.
KW - adverse events, BRAF-mutated advanced melanoma, efficacy, encorafenib plus binimetinib, second line
UR - http://www.scopus.com/inward/record.url?scp=85096766737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096766737&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.15688
DO - 10.1111/1346-8138.15688
M3 - Article
C2 - 33179310
AN - SCOPUS:85096766737
SN - 0385-2407
VL - 48
SP - 397
EP - 400
JO - Journal of Dermatology
JF - Journal of Dermatology
IS - 3
ER -